{
  "id": "df195a9fda280c6a",
  "title": "STAT+: Pharmalittle: We\u2019re reading about China\u2019s homegrown GLP-1 drugs, a puzzling FDA rejection, and more",
  "description": "The FDA rejected a Disc Medicine therapy for a rare blood disorder, the first experimental drug to go through a new program to fast-track drug reviews",
  "content": "The FDA rejected a Disc Medicine therapy for a rare blood disorder, the first experimental drug to go through a new program to fast-track drug reviews",
  "source": "STAT",
  "source_url": "https://www.statnews.com/pharmalot/2026/02/17/india-ireland-china-glp-lilly-novo-obesity-vaccines-peanuts-africa/?utm_campaign=rss",
  "published_at": "2026-02-17T14:21:26+00:00",
  "fetched_at": "2026-02-18T00:30:07.542614+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "china",
    "drug",
    "fda"
  ],
  "location": null,
  "raw_data": {
    "title": "STAT+: Pharmalittle: We\u2019re reading about China\u2019s homegrown GLP-1 drugs, a puzzling FDA rejection, and more",
    "description": "The FDA rejected a Disc Medicine therapy for a rare blood disorder, the first experimental drug to go through a new program to fast-track drug reviews",
    "url": "https://www.statnews.com/pharmalot/2026/02/17/india-ireland-china-glp-lilly-novo-obesity-vaccines-peanuts-africa/?utm_campaign=rss",
    "published": "2026-02-17T14:21:26+00:00",
    "source": "STAT"
  }
}